Illumina, Inc. $ILMN Shares Sold by Yousif Capital Management LLC

by · The Cerbat Gem

Yousif Capital Management LLC trimmed its position in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 10.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,790 shares of the life sciences company’s stock after selling 4,917 shares during the quarter. Yousif Capital Management LLC’s holdings in Illumina were worth $4,064,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Corvex Management LP raised its position in shares of Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after buying an additional 2,129,449 shares during the period. AQR Capital Management LLC increased its stake in Illumina by 361.7% during the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock worth $165,484,000 after acquiring an additional 1,662,093 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in Illumina by 11,714.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock valued at $92,184,000 after purchasing an additional 1,152,048 shares during the period. Edmond DE Rothschild Holding S.A. lifted its stake in shares of Illumina by 140.1% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after purchasing an additional 833,750 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its stake in shares of Illumina by 1,558.0% in the 2nd quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock valued at $69,528,000 after purchasing an additional 684,802 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 0.2%

NASDAQ ILMN opened at $136.43 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The firm has a market cap of $20.85 billion, a price-to-earnings ratio of 30.59, a PEG ratio of 2.42 and a beta of 1.44. The firm has a 50 day simple moving average of $121.66 and a 200-day simple moving average of $105.84. Illumina, Inc. has a one year low of $68.70 and a one year high of $153.06.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ILMN shares. Cowen reissued a “hold” rating on shares of Illumina in a research report on Friday, October 31st. Robert W. Baird set a $109.00 price target on shares of Illumina in a research report on Friday, October 31st. Canaccord Genuity Group boosted their price target on shares of Illumina from $112.00 to $130.00 and gave the company a “hold” rating in a research note on Monday. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 2nd. Finally, UBS Group lifted their target price on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus target price of $118.31.

Get Our Latest Research Report on ILMN

Illumina Company Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Featured Articles